Search results for "Open"

showing 10 items of 3963 documents

Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice

2015

Producción Científica

AdultMalemedicine.medical_specialtyRiñones - TrasplanteCongenital cytomegalovirus infectionCytomegaloviruskidney transplantationSIDA (Enfermedad)Kaplan-Meier EstimateDiseaseAntiviral AgentsAsymptomaticRisk FactorsInternal medicineseropositive recipientpreemptive therapymedicineHumansValganciclovirProspective StudiesRenal InsufficiencyPropensity ScoreGanciclovircytomegalovirusKidney transplantationAgedProportional Hazards ModelsTransplantation3205.06 Nefrologíabusiness.industryProportional hazards modelIncidenceIncidence (epidemiology)antiviral prophylaxisMiddle Agedmedicine.diseaseKidney TransplantationDiscontinuationSurgerymulticenter studySpainCytomegalovirus InfectionsPropensity score matchingFemalemedicine.symptombusinessImmunosuppressive AgentsGlomerular Filtration Rate
researchProduct

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Durability of open popliteal artery aneurysm repair

2014

Objective The objective of this study was to analyze our long-term results after open surgery for popliteal artery aneurysm. Methods Records of patients who received surgery between 1998 and 2010 were retrieved from a computerized database and analyzed retrospectively. End points of the study were perioperative mortality and morbidity and patency and limb salvage rate. Results Two hundred and six popliteal aneurysms (median diameter, 30 mm; interquartile range, 18 mm) were treated (161 elective, 45 emergent) in 154 patients (mean age, 67 ± 11 years) using vein grafts (82%) via the medial approach (92%). Above-knee popliteal artery (45%) and below-knee popliteal artery (65%) were the predomi…

AdultMalemedicine.medical_specialtyUmbilical VeinsLimb salvageVein graftInterquartile rangemedicine.arteryMedicineHumansPopliteal ArteryAgedRetrospective StudiesComputerized databasesAged 80 and overUltrasonography Doppler Duplexbusiness.industryOpen surgeryAnastomosis SurgicalPopliteal artery aneurysmAngiography Digital SubtractionPerioperativeMiddle AgedPlastic Surgery ProceduresAneurysmPopliteal arterySurgeryTreatment OutcomeAnesthesiaFemaleSurgerybusinessCardiology and Cardiovascular MedicineVascular Surgical ProceduresMagnetic Resonance AngiographyFollow-Up StudiesForecastingJournal of Vascular Surgery
researchProduct

Management of symptomatic benign prostatic hyperplasia in southern Italy: a retrospective analysis of the Sicilian-Calabrian Society of Urology (SSCU…

2002

<i>Introduction:</i> The availability of new pharmacological and surgical options is responsible for important changes in the management of symptomatic benign prostate hyperplasia (BPH). The Sicilian-Calabrian Society of Urology performed a retrospective survey to assess the management of BPH in southern Italy in 1997 and 1998. <i>Patients and Methods:</i> A 3-page questionnaire was sent to the 36 urological units of these two regions. The real number of patients treated was required. The numbers were checked with data obtained from the Health Regional Offices. <i>Results:</i> Twenty-six urological units (72.3%) replied. Almost all patients underwent urin…

AdultMalemedicine.medical_specialtyUrinalysisUrologymedicine.medical_treatmentUrologyProstatic HyperplasiaTransurethral prostatectomyProstateEpidemiologymedicineHumansMinimally Invasive Surgical ProceduresTransurethral resection of the prostateAgedRetrospective StudiesAged 80 and overProstatectomymedicine.diagnostic_testUrinary retentionbusiness.industryMiddle Agedmedicine.anatomical_structureItalyInternational Prostate Symptom Scoremedicine.symptombusinessOpen ProstatectomyUrologia internationalis
researchProduct

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

2019

International audience; Background: Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated) improves progression-free survival in patients with advanced Hodgkin lymphoma compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), but is associated with increased risks of haematological toxicity, secondary myelodysplasia or leukaemia, and infertility. We investigated whether PET monitoring during treatment could allow dose de-escalation by switching regimen (BEACOPPescalated to ABVD) in early responders without loss of disease control compared with standard treatment without PET monitoring.Methods: AHL201…

AdultMalemedicine.medical_specialtyVincristineDacarbazine[SDV]Life Sciences [q-bio]Salvage therapy[SDV.CAN]Life Sciences [q-bio]/CancerProcarbazineGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansComputingMilieux_MISCELLANEOUSNeoplasm Stagingbusiness.industryStandard treatmentmedicine.diseaseHodgkin Disease3. Good healthVinblastineDrug Therapy Computer-Assisted[SDV] Life Sciences [q-bio]OncologyABVD030220 oncology & carcinogenesisPositron-Emission TomographyFemalebusinessFebrile neutropenia030215 immunologymedicine.drug
researchProduct

Impact of whole-body computed tomography on mortality and surgical management of severe blunt trauma

2012

International audience; IntroductionThe mortality benefit of whole-body computed tomography (CT) in early trauma management remains controversial and poorly understood. The objective of this study was to assess the impact of whole-body CT compared with selective CT on mortality and management of patients with severe blunt trauma.MethodsThe FIRST (French Intensive care Recorded in Severe Trauma) study is a multicenter cohort study on consecutive patients with severe blunt trauma requiring admission to intensive care units from university hospital trauma centers within the first 72 hours. Initial data were combined to construct a propensity score to receive whole-body CT and selective CT used…

AdultMalemedicine.medical_specialty[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO][SHS.INFO]Humanities and Social Sciences/Library and information sciencesCritical Care and Intensive Care MedicineWounds Nonpenetrating[SHS.INFO] Humanities and Social Sciences/Library and information sciencesCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineIntensive care[ SHS.INFO ] Humanities and Social Sciences/Library and information sciences[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]MedicineHumans030212 general & internal medicineProspective StudiesYoung adultMortalityProspective cohort studyTrauma Severity Indicesblunt trauma[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]business.industryMortality rateResearchDisease Management030208 emergency & critical care medicineMiddle Aged3. Good healthSurgeryBlunt traumaPropensity score matchingInjury Severity ScoreFemalebusinessTomography X-Ray ComputedCohort study
researchProduct

Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies.

2020

AbstractThree selected casuistic studies of individual patient problems from my long-standing professional experience are presented. I intend to highlight the potential contribution of case studies, including new approaches of laboratory investigation, for the advancement of pathophysiological knowledge and would encourage to “rehabilitate” the low academic profile generally attributed to “case reports.”

AdultMalemedicine.medical_specialtybusiness.industrymedicine.drug_classThrombotic thrombocytopenic purpuraMEDLINEHematology030204 cardiovascular system & hematologyVitamin K antagonistmedicine.disease03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisMedicineHumansFemalebusinessIntensive care medicineLaboratoriesProblem SolvingHamostaseologie
researchProduct

The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study.

2005

AbstractIn contrast with extensive documentation in patients treated with unfractionated heparin (UFH), the incidence of heparin-induced thrombocytopenia (HIT) in medical patients receiving low-molecular-weight heparin (LMWH) is less well defined. In a prospective cohort study, the platelet count was monitored in 1754 consecutive patients referred to 17 medical centers and treated with LMWH for prophylaxis or treatment of thromboembolic disorders. The diagnosis of HIT was accepted in case of a platelet drop of at least 50%, the absence of obvious explanations for thrombocytopenia, and the demonstration of heparin-dependent IgG antibodies. HIT developed in 14 patients (0.80%; 95% CI, 0.43%-1…

AdultMalemedicine.medical_specialtymedicine.drug_classImmunologyLow molecular weight heparinheparinPlatelet Factor 4BiochemistryCohort StudiesRisk FactorsHeparin-induced thrombocytopeniaInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)IncidenceCell BiologyHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaSurgeryClinical trialTreatment OutcomeFemaleComplicationbusinessCohort studymedicine.drugBlood
researchProduct

Etoposide Treatment in Recurrent Medulloblastoma

1994

Five consecutive patients with recurrent medulloblastoma received etoposide 120 mg/m2 for 5 to 7 days at 2 to 4-week intervals. Three patients with neuroaxis dissemination received additional intrathecal chemotherapy with methotrexate, cytosine arabinoside and prednisone. Toxicity consisted of alopecia and mild neutropenia. Complete response was registered in two patients, partial response in one. Median survival was 19 months with the 3 responders living 6, 30 and 60+ months. Etoposide seems to be an active agent in medulloblastoma.

AdultMalemedicine.medical_specialtymedicine.medical_treatmentNeutropeniaGastroenterologyRecurrencePrednisoneInternal medicinemedicineHumansSpinal Cord NeoplasmsNeoplasm MetastasisChildEtoposideEtoposideMedulloblastomaChemotherapyBrain Neoplasmsbusiness.industryGeneral MedicineRecurrent MedulloblastomaPrognosismedicine.diseaseFrontal LobeSurgeryTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthToxicityFemaleMethotrexateNeurology (clinical)Tomography X-Ray ComputedbusinessMedulloblastomamedicine.drugNeuropediatrics
researchProduct

Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia…

2006

Background The aim of the study was to test the clinical efficacy and toxicity profile of gemcitabine (GEM) in combination with cisplatin (CDDP) in a series of patients affected by unresectable and/or metastatic biliary tree carcinoma (BTC) previously untreated with chemotherapy. Patients and methods Overall 38 consecutive patients who satisfied eligibility criteria (10 with gall-bladder carcinoma and 28 with bile duct carcinoma) were included in this phase II study. Median age was 61 years with median PS 1. Treatment included GEM 1000 mg/m2/week as 30 min i.v. on days 1 and 8, and CDDP 75–80 mg/m2 on day 1 with adequate hydration protocol and forced diuresis. Treatment was repeated every 3…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchNeutropeniaDeoxycytidineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansAgedChemotherapybusiness.industryHematologyMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryRegimenBile Duct NeoplasmsOncologyToxicityFemaleGallbladder NeoplasmsCisplatinbusinessProgressive diseasemedicine.drugAnnals of Oncology
researchProduct